Ignite Creation Date:
2024-05-06 @ 7:17 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02504645
Status:
COMPLETED
Last Update Posted:
2019-04-11
First Post:
2015-07-17
Brief Title:
A 52-Week Randomized Double-Blind Parallel-Group Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Sponsor:
ImmuPharma
Organization:
ImmuPharma
Organization Data
Organization:
ImmuPharma
Class:
INDUSTRY
Study ID:
IPP-201101005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
ImmuPharma
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None